"Immutep will apply the non-dilutive funding towards furthering its current active clinical trial programs for its lead product candidate, efti. The expected cash reach of the Company extends into early calendar year 2026."
Ann: Immutep receives Australian R&D Tax Incentive, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.005(1.12%) |
Mkt cap ! $534.9M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.5¢ | 44.0¢ | $432.5K | 968.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 10175 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 26893 | 2 |
View Market Depth
| Last trade - 16.10pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
44.5¢ |
Change
0.005 ( 0.16 %) |
||||
| Open | High | Low | Volume | ||
| 44.5¢ | 45.5¢ | 44.5¢ | 305959 | ||
| Last updated 15.59pm 27/05/2024 ? | |||||
| IMM (ASX) Chart |